PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 8, Pages 2054
Publisher
MDPI AG
Online
2020-07-27
DOI
10.3390/cancers12082054
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
- (2020) Adrienne G. Waks et al. ANNALS OF ONCOLOGY
- PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1
- (2020) Rimma Belotserkovskaya et al. Nature Communications
- Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
- (2020) Brian T. Burgess et al. Diagnostics
- Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
- (2020) Andrew D. Simmons et al. BMC CANCER
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
- (2020) Joyce F. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers
- (2020) Timothy A. Yap et al. Cancer Discovery
- Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
- (2019) Zebin Wang et al. Scientific Reports
- Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
- (2019) Elizabeth L. Christie et al. Nature Communications
- F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy
- (2019) Aleksandra I. Adamovich et al. MOLECULAR CELL
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
- (2019) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
- (2019) J F Liu et al. ANNALS OF ONCOLOGY
- Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition
- (2019) Rashid Gabbasov et al. CANCER BIOLOGY & THERAPY
- N6-methylation of adenosine (m6A) of FZD10 mRNA contributes to PARP inhibitor resistance
- (2019) Takeshi Fukumoto et al. CANCER RESEARCH
- DNA double-strand break repair pathway choice - from basic biology to clinical exploitation
- (2019) Ron D. Jachimowicz et al. CELL CYCLE
- Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.
- (2019) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
- (2019) Alanna R. Kaplan et al. Science Translational Medicine
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
- (2019) Yong Fang et al. CANCER CELL
- CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes
- (2019) Anil Paul Chirackal Manavalan et al. EMBO REPORTS
- Activation of Wnt signaling promotes olaparib resistant ovarian cancer
- (2019) Tomomi M. Yamamoto et al. MOLECULAR CARCINOGENESIS
- Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer
- (2019) Alan P Lombard et al. Translational Oncology
- Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
- (2019) Jian-Fang Ning et al. Nature Communications
- CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation
- (2019) Malgorzata Krajewska et al. Nature Communications
- BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
- (2019) Timo Reisländer et al. Nature Communications
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
- (2019) Kalindi Parmar et al. CLINICAL CANCER RESEARCH
- Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations.
- (2019) Pyoung Hwa Park et al. MOLECULAR CANCER THERAPEUTICS
- Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition‐mediated genomic instability, inflammatory signaling and cytotoxicity in BRCA2‐deficient cancer cells
- (2019) Pepijn M. Schoonen et al. Molecular Oncology
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
- (2019) Victor Quereda et al. CANCER CELL
- The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models
- (2019) Antje M. Wengner et al. MOLECULAR CANCER THERAPEUTICS
- Radiation responses of 2D and 3D glioblastoma cells: a novel, 3D-specific radioprotective role of VEGF/Akt signaling through functional activation of NHEJ
- (2019) Natividad Gomez-Roman et al. MOLECULAR CANCER THERAPEUTICS
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
- (2019) Sylvie M. Noordermeer et al. TRENDS IN CELL BIOLOGY
- Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma
- (2019) Zachary L. Watson et al. Clinical Epigenetics
- Diverse mechanisms of PARP inhibitor resistance in ovarian cancer
- (2019) Matthew John Wakefield et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
- (2019) Du-Bois Asante et al. CANCER LETTERS
- BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
- (2019) Yifan Wang et al. Nature Communications
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- (2018) C Cruz et al. ANNALS OF ONCOLOGY
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity
- (2018) Rajat Gupta et al. CELL
- BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy
- (2018) Erica L. Gornstein et al. Clinical Breast Cancer
- FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
- (2018) Gwynn Ison et al. CLINICAL CANCER RESEARCH
- The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
- (2018) Andrew J. Wilson et al. GYNECOLOGIC ONCOLOGY
- SLFN11 Blocks Stressed Replication Forks Independently of ATR
- (2018) Junko Murai et al. MOLECULAR CELL
- Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells
- (2018) Kristen E Clements et al. NUCLEIC ACIDS RESEARCH
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
- (2018) Stephen J. Pettitt et al. Nature Communications
- MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models
- (2018) Francesca Vena et al. Oncotarget
- Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2 -Mutated Carcinomas
- (2018) Khyati Meghani et al. Cell Reports
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- SHLD2/FAM35A co‐operates with REV7 to coordinate DNA double‐strand break repair pathway choice
- (2018) Steven Findlay et al. EMBO JOURNAL
- 53BP1 cooperation with the REV7–shieldin complex underpins DNA structure-specific NHEJ
- (2018) Hind Ghezraoui et al. NATURE
- The shieldin complex mediates 53BP1-dependent DNA repair
- (2018) Sylvie M. Noordermeer et al. NATURE
- Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
- (2018) Olga Kondrashova et al. Nature Communications
- BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance
- (2018) Joseph Nacson et al. Cell Reports
- Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors
- (2018) Asima Mukhopadhyay et al. BIOCHEMICAL PHARMACOLOGY
- Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
- (2018) Darren R. Hodgson et al. BRITISH JOURNAL OF CANCER
- EGFR and c-MET cooperate to enhance resistance to PARP inhibitors in hepatocellular carcinoma
- (2018) Qiongzhu Dong et al. CANCER RESEARCH
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers
- (2018) Antonio Marzio et al. MOLECULAR CELL
- CDK12 regulates DNA repair genes by suppressing intronic polyadenylation
- (2018) Sara J. Dubbury et al. NATURE
- DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
- (2018) Yizhou Joseph He et al. NATURE
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2018) Kevin K Lin et al. Cancer Discovery
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
- (2018) Roman M. Chabanon et al. JOURNAL OF CLINICAL INVESTIGATION
- ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
- (2017) Stephanie A. Yazinski et al. GENES & DEVELOPMENT
- BRCA1/2 reversion mutations revealed in breast and gynecologic cancers sequenced during routine clinical care using tissue or liquid biopsy.
- (2017) Paul Mayor et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
- (2017) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
- (2017) Elizabeth L. Christie et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors
- (2017) Leslie A. Parsels et al. MOLECULAR CANCER RESEARCH
- Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers
- (2017) Angelo Taglialatela et al. MOLECULAR CELL
- EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
- (2017) Beatrice Rondinelli et al. NATURE CELL BIOLOGY
- BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance
- (2017) Alexandra A Duarte et al. NATURE METHODS
- The HSP90 chaperone machinery
- (2017) Florian H. Schopf et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- G9a coordinates with the RPA complex to promote DNA damage repair and cell survival
- (2017) Qiaoyan Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition
- (2017) Lu Yang et al. Science Translational Medicine
- Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
- (2017) Chaoyang Sun et al. Science Translational Medicine
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
- (2017) David Quigley et al. Cancer Discovery
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer
- (2017) Ethan Brill et al. Oncotarget
- Protein-lysine methyltransferases G9a and GLP1 promote responses to DNA damage
- (2017) Vasudeva Ginjala et al. Scientific Reports
- Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer
- (2016) U.A. Matulonis et al. ANNALS OF ONCOLOGY
- Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germlineBRCA1/2mutation: a multistudy analysis of response rates and safety
- (2016) U. A. Matulonis et al. ANNALS OF ONCOLOGY
- C1q and HMGB1 reciprocally regulate human macrophage polarization
- (2016) M. Son et al. BLOOD
- ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
- (2016) Aparajitha Vaidyanathan et al. BRITISH JOURNAL OF CANCER
- The BRCA1- 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
- (2016) Y. Wang et al. CANCER RESEARCH
- A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy
- (2016) M. Makvandi et al. CANCER RESEARCH
- Combining Molecularly Targeted Agents: Is More Always Better?
- (2016) Raghav Sundar et al. CLINICAL CANCER RESEARCH
- RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
- (2016) Yajing Liu et al. CLINICAL CANCER RESEARCH
- Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
- (2016) E. H. Stover et al. CLINICAL CANCER RESEARCH
- Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models
- (2016) Hyoung Kim et al. CLINICAL CANCER RESEARCH
- The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma
- (2016) Mette Hjortkjær et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance
- (2016) Yifan Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
- (2016) Yi Du et al. NATURE MEDICINE
- Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion
- (2016) Ashish Juvekar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulation of Single-Strand Annealing and its Role in Genome Maintenance
- (2016) Ragini Bhargava et al. TRENDS IN GENETICS
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
- (2016) Xia Ding et al. Nature Communications
- LIG4 mediates Wnt signalling-induced radioresistance
- (2016) Sohee Jun et al. Nature Communications
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1 -Mutant Ovarian Cancer
- (2016) Young Eun Choi et al. Cell Reports
- The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
- (2016) Jiandong Chen Cold Spring Harbor Perspectives in Medicine
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy
- (2015) Minghua Yang et al. Autophagy
- The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancer
- (2015) Jing Huang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- Resistance to therapy inBRCA2mutant cells due to loss of the nucleosome remodeling factor CHD4
- (2015) Shawna Guillemette et al. GENES & DEVELOPMENT
- The Replication Checkpoint Prevents Two Types of Fork Collapse without Regulating Replisome Stability
- (2015) Huzefa Dungrawala et al. MOLECULAR CELL
- Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
- (2015) Raphael Ceccaldi et al. NATURE
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex
- (2015) Kingsley M. Ekumi et al. NUCLEIC ACIDS RESEARCH
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
- (2014) D. Karnak et al. CLINICAL CANCER RESEARCH
- Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression
- (2014) X. Wei Meng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
- (2014) Poorval M. Joshi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PARP-1 Mediates LPS-Induced HMGB1 Release by Macrophages through Regulation of HMGB1 Acetylation
- (2014) Zhiyong Yang et al. JOURNAL OF IMMUNOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers
- (2014) Kimiyo N. Yamamoto et al. PLoS One
- VEGFR3 Inhibition Chemosensitizes Ovarian Cancer Stemlike Cells through Down-Regulation of BRCA1 and BRCA2
- (2014) Jaeyoung Lim et al. NEOPLASIA
- Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
- (2013) R. J. Kurman ANNALS OF ONCOLOGY
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1
- (2012) Alex Pines et al. JOURNAL OF CELL BIOLOGY
- Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability
- (2012) R. Kumareswaran et al. JOURNAL OF CELL SCIENCE
- BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation
- (2012) S. R. Stecklein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy
- (2012) Farah L. Rehman et al. Cancer Discovery
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11
- (2011) Katharina Schlacher et al. CELL
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytosolic DNA-Activated Human Dendritic Cells Are Potent Activators of the Adaptive Immune Response
- (2011) K. Kis-Toth et al. JOURNAL OF IMMUNOLOGY
- E2F7 represses a network of oscillating cell cycle genes to control S-phase progression
- (2011) Bart Westendorp et al. NUCLEIC ACIDS RESEARCH
- Comprehensive Analysis of Missense Variations in the BRCT Domain of BRCA1 by Structural and Functional Assays
- (2010) Megan S. Lee et al. CANCER RESEARCH
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
- (2010) Ahmed Ashour Ahmed et al. JOURNAL OF PATHOLOGY
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
- (2010) Peter Bouwman et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- PARP1 ADP-ribosylates lysine residues of the core histone tails
- (2010) Simon Messner et al. NUCLEIC ACIDS RESEARCH
- PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation
- (2010) R Deng et al. ONCOGENE
- A Selective Requirement for 53BP1 in the Biological Response to Genomic Instability Induced by Brca1 Deficiency
- (2009) Liu Cao et al. MOLECULAR CELL
- Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance
- (2008) N. Chan et al. CANCER RESEARCH
- Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance
- (2008) E. M. Swisher et al. CANCER RESEARCH
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started